Oppenheimer Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report released on Tuesday, Marketbeat reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research analysts also recently issued reports on the company. JPMorgan Chase & Co. lifted their […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report released on Tuesday, Marketbeat reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research analysts also recently issued reports on the company. JPMorgan Chase & Co. lifted their […]
